作者: Matthew S. Bosner , Andrew A. Wolff , Richard E. Ostlund, Jr.
关键词:
摘要: Two clinical trials were performed to test the hypothesis that CVT-1, a potent inhibitor of pancreatic cholesterol esterase, reduces percent absorption and LDL in humans. Measurements made with deuterated tracers given orally intravenously detected plasma by new technique using negative ion mass spectrometry. Study 1 was randomized, double-blind parallel study CVT-1 treatment at doses 0, 300, 1500, 3000 mg/day 19 subjects. Percent measured baseline again after 2 6 weeks showed no effect unchanged. II randomized open-label crossover comparison between as 1000 mg three times daily for 187.5 hourly 16 hours/day weeks. not different periods. We conclude esterase is required unesterified human